Robert J. DelAversano

Vice President, Finance, Principal Financial Officer and Principal Accounting Officer at Grace Therapeutics.

Raised on Grace Therapeutics filings

$15M

of $30M offered across 1 Form D filing

Form D filings: 1
Teammates: 8
Last filing: Feb 25, 2025

Company

Grace Therapeutics

Biotech · Princeton, NJ

IV treatment for a rare type of brain bleed

IV treatment for a rare type of brain bleed

Investors: 14
Still open: $15M

Investors: 14
Sector: Biotech
HQ: Princeton, NJ

Grace Therapeutics filings

Grace Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Feb 25, 2025	Equity	$15M/ $30M	Form D

EquityFiled Feb 25, 2025Form D
$15M/ $30M

Works with

Also named on Grace Therapeutics filings

Prashant KohliChief Executive Officer, Form D signerForm D signer Amresh KumarVP of Program Management A. Brian DavisDirector Dr. R. Loch MacdonaldChief Medical Officer S. George KottayilDirector Carrie D'AndreaVP Clinical Operations Edward NeugeborenDirector Vimal KavuruDirector